# Cancer Drugs

| Drug            | Target Gene        | Objective                                                                 | Reference |
|-----------------|--------------------|---------------------------------------------------------------------------|-----------|
| 5-FU            | TYMS - DNA         | DNA Replication Inhibitor <br> DNA/RNA Damage                             | [1]       |
| ABT-888         | PARP               | DNA Repair Inhibitor                                                      | [2]       |
| Sunitinib       | RTK Groups         | Cell Growth Blocker                                                       | [3]       |
| Sorafenib       | RTK Groups         | Cell Growth Blocker                                                       | [4]       |
| Erlotinib       | EGFR               | Proliferation Inhibitor <br> Apoptosis Activator                          | [5]       |
| Oxaliplatin     | DNA                | DNA Damage                                                                | [6]       |
| Vinblastine     | Tubulin Groups     | Cell Division Inhibitor                                                   | [7]       |
| AZD1775         | Wee1               | Apoptosis Activator <br> (Mitosis Activator with Damaged DNA)             | [8]       |
| L-778123        | FNTA               | Cell Proliferation <br> (RAS) Inhibitor                                   | [9]       |
| BEZ-235         | PI3K - mTOR        | Cell Growth Blocker <br> Metabolism Blocker                               | [10]      |
| Dinaciclib      | CDK                | Cell Cycle Blocker                                                        | [11]      |
| Geldanamycin    | HSP90              | Onco-protein Stabilization Inhibitor                                      | [12]      |
| MK-2206         | AKT                | Down-regulation of Cell Growth and Proliferation                          | [13]      |
| MK-4827         | PARP               | DNA Repair Inhibitor                                                      | [14]      |
| MK-5108         | AURKA              | Mitosis Inhibitor                                                         | [15]      |
| MK-8669         | mTOR               | Cell Growth Blocker <br> Metabolism Blocker                               | [16]      |
| MK-8776         | CHEK1              | DNA Damage Accumulation <br> Cell Cycle Breaker                           | [17]      |
| MRK-003         | γ-Secretase        | Proliferation Inhibitor <br> Apoptosis Activator <br> (Notch Suppressor)  | [18]      |
| PD-0325901      | MEK1 - MEK2        | Proliferation Inhibitor <br> Apoptosis Activator                          | [19]      |
| Bortezomib      | 26S Proteasome     | Cell Cycle Breaker <br> Apoptosis Activator                               | [20]      |
| Dasatinib       | Abl/Src Kinase     | Cell Growth Blocker                                                       | [21]      |
| Lapatinib       | EGFR-HER2          | Cell Growth Blocker                                                       | [22]      |
| Temozolomide    | DNA                | DNA Damage                                                                | [23]      |
| Zolinza         | HDAC Groups        | Cell Growth Inhibitor <br> Apoptosis Activator                            | [24]      |
| Carboplatin     | DNA                | DNA Damage                                                                | [25]      |
| Cyclophosphamide| DNA                | DNA Damage                                                                | [26]      |
| Dexamethasone   | NR3C1              | Immunomodulator                                                           | [27]      |
| Doxorubicin     | TOP2A - TOP2B      | Double Strand Break Accumulation                                          | [28]      |
| Etoposide       | TOP2A              | Double Strand Break Accumulation                                          | [29]      |
| Gemcitabine     | RRM1               | DNA Synthesis Inhibitor                                                   | [30]      |
| Metformin       | AMPK               | Proliferation Inhibitor <br> Apoptosis Activator                          | [31]      |
| Vinorelbine     | Tubulin Groups     | Cell Division Inhibitor                                                   | [32]      |
| Methotrexate    | DHFR               | Nucleotide Synthesis Inhibitor                                            | [33]      |
| Paclitaxel      | Tubulin Groups     | Cell Division Inhibitor                                                   | [34]      |
| Topotecan       | TOP1               | DNA Strand Break Accumulation                                             | [35]      |
| SN-38           | TOP1               | DNA Strand Break Accumulation                                             | [36]      |


# References:
These references are the research studies carried out on these cancer drugs and their targeted gene products. They are not drugs' original publications.

* [1]: 5-fluorouracil: mechanisms of action and clinical strategies.
* [2]: ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
* [3]: Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
* [4]: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
* [5]: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
* [6]: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.
* [7]: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
* [8]: Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
* [9]: Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123.
* [10]: PI3K inhibitors in cancer: clinical implications and adverse effects.
* [11]: CDK inhibitors in cancer therapy, an overview of recent development.
* [12]: Role of HSP90 in Cancer.
* [13]: Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use.
* [14]: MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
* [15]: Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.
* [16]: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regi- mens.
* [17]: ATR/CHK1 inhibitors and cancer therapy.
* [18]: The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
* [19]: A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer.
* [20]: Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
* [21]: Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
* [22]: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
* [23]: Current and future developments in the use of temozolomide for the treatment of brain tumours.
* [24]: Phase II trial of the histone deacetylase inhibitor vorinostat (ZolinzaTM, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
* [25]: Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.
* [26]: Cyclophosphamide and can- cer: golden anniversary.
* [27]: Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo- immunotherapy strategies.
* [28]: Targeting DNA topoisomerase II in cancer chemotherapy.
* [29]: Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.
* [30]: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
* [31]: Metformin: activation of 5 AMP-activated protein kinase and its emerging potential beyond anti- hyperglycemic action.
* [32]: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
* [33]: Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation.
* [34]: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
* [35]: Inhibition of topoisomerase (DNA) I (TOP1): DNA dam- age repair and anticancer therapy.
* [36]: Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
